Update cookies preferences

E-book: Evidence-Based Cardiology

5.00/5 (2 ratings by Goodreads)
,
  • Format: 540 pages
  • Pub. Date: 23-Aug-2016
  • Publisher: Lippincott Williams and Wilkins
  • Language: eng
  • ISBN-13: 9781496375117
Other books in subject:
  • Format - EPUB+DRM
  • Price: 57,64 €*
  • * the price is final i.e. no additional discount will apply
  • Add to basket
  • Add to Wishlist
  • This ebook is for personal use only. E-Books are non-refundable.
Evidence-Based CardiologyLarger Image
  • Format: 540 pages
  • Pub. Date: 23-Aug-2016
  • Publisher: Lippincott Williams and Wilkins
  • Language: eng
  • ISBN-13: 9781496375117
Other books in subject:

DRM restrictions

  • Copying (copy/paste):

    not allowed

  • Printing:

    not allowed

  • Usage:

    Digital Rights Management (DRM)
    The publisher has supplied this book in encrypted form, which means that you need to install free software in order to unlock and read it.  To read this e-book you have to create Adobe ID More info here. Ebook can be read and downloaded up to 6 devices (single user with the same Adobe ID).

    Required software
    To read this ebook on a mobile device (phone or tablet) you'll need to install this free app: PocketBook Reader (iOS / Android)

    To download and read this eBook on a PC or Mac you need Adobe Digital Editions (This is a free app specially developed for eBooks. It's not the same as Adobe Reader, which you probably already have on your computer.)

    You can't read this ebook with Amazon Kindle

With some help from fellow cardiologists, Steinberg and Cannon systematically summarize major trial data and place the information from these annotated studies in context. They present the results of major randomized trials in six major topics areas, including the design, study population, treatment regimen, and results. The areas are preventive cardiology, coronary revascularization and percutaneous procedures, unstable angina/non-ST elevation myocardial infarction, ST elevation myocardial infarction, heart failure, and arrhythmias. For this edition they have dropped some older trials to limit the length of the book, and have lengthened the chapter overviews preceding the annotated references with more attention to relevant ACC/AHA practice guidelines. Annotation ©2015 Ringgold, Inc., Portland, OR (protoview.com)

Get quick, portable access to the evidence you need to make effective clinical decisions! Evidence-Based Cardiology succinctly summarizes all the clinical trials that affect the practice of cardiovascular medicine, making it easy for you to implement the most appropriate diagnostic tests and treatments for your patients.
  • Apply the latest knowledge on atrial fibrillation and heart failure, including novel anticoagulants, new medical therapies, new devices including ablation and resynchronization and other advanced therapies.
  • Select the best interventions for acute coronary syndrome with coverage of new antiplatelet strategies, management strategy updates, and significant data on outcomes and guideline adherence.
  • Navigate controversies across your entire field with in-depth chapters exploring all areas of preventive cardiology, coronary revascularization and percutaneous procedures, unstable angina/non-ST elevation myocardial infarction, ST-elevation myocardial infarction, heart failure, and arrhythmias.
  • Look up all essential randomized clinical trials and understand their implications with concise summaries of trial design, study population, treatment regimen, and results, together with relevant ACC/AHA Practice Guidelines.
Now included with the print edition, enjoy the bundled interactive eBook edition, which can be downloaded to your smartphone or tablet, or accessible online and includes features like:
  • Complete content with enhanced navigation
  • A powerful search that pulls results from content in the book, your notes, and even the web
  • Cross-linked pages, references, and more for easy navigation
  • Highlighting tool for easier reference of key content throughout the text
  • Ability to take and share notes with friends and colleagues
  • Quick reference tabbing to save your favorite content for future use


Get quick, portable access to the evidence you need to make effective clinical decisions! Evidence-Based Cardiology succinctly summarizes all the clinical trials that affect the practice of cardiovascular medicine, making it easy for you to implement the most appropriate diagnostic tests and treatments for your patients.
  • Apply the latest knowledge on atrial fibrillation and heart failure, including novel anticoagulants, new medical therapies, new devices including ablation and resynchronization and other advanced therapies.
  • Select the best interventions for acute coronary syndrome with coverage of new antiplatelet strategies, management strategy updates, and significant data on outcomes and guideline adherence.
  • Navigate controversies across your entire field with in-depth chapters exploring all areas of preventive cardiology, coronary revascularization and percutaneous procedures, unstable angina/non-ST elevation myocardial infarction, ST-elevation myocardial infarction, heart failure, and arrhythmias.
  • Look up all essential randomized clinical trials and understand their implications with concise summaries of trial design, study population, treatment regimen, and results, together with relevant ACC/AHA Practice Guidelines.
Now included with the print edition, enjoy the bundled interactive eBook edition, which can be downloaded to your smartphone or tablet, or accessible online and includes features like:
  • Complete content with enhanced navigation
  • A powerful search that pulls results from content in the book, your notes, and even the web
  • Cross-linked pages, references, and more for easy navigation
  • Highlighting tool for easier reference of key content throughout the text
  • Ability to take and share notes with friends and colleagues
  • Quick reference tabbing to save your favorite content for future use
Contributors iii
Preface v
Chapter 1 Preventive Cardiology: Risk Factors for Coronary Artery Disease and Primary and Secondary Prevention 1(109)
Christopher P. Cannon
Benjamin A. Steinberg
Alexander C. Fanaroff
Cholesterol And Lipids
1(10)
Epidemiology
1(2)
ACC/AHA Guidelines
3(1)
Drugs
3(8)
Bile Resins (e.g., Cholestyramine, Colestipol)
3(2)
Fibric Acid Derivatives (e.g., Gemfibrozil, Fenofibrate)
5(1)
Cholesterol Absorption Inhibitors
5(1)
3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (Statins)
6(1)
Primary Prevention Trials
7(1)
Secondary Prevention Trials
8(1)
Combined Primary and Secondary Prevention Trials
8(1)
Early Statin Initiation Trials
9(1)
Raising HDL Cholesterol
10(1)
Niacin
10(1)
Cholesterol Ester Transfer Protein Inhibitors
11(1)
Diet And Vitamins
11(2)
Special Diets
11(2)
Alcohol
13(1)
Lifestyle Factors
13(2)
Obesity
13(1)
Exercise
14(1)
Smoking
15(1)
Metabolic Syndrome
15(1)
Diabetes
16(2)
Hypertension
18(4)
Epidemiology
18(1)
Etiology
18(1)
Diagnosis
18(2)
Treatment
20(2)
Nonpharmacologic
20(1)
Pharmacologic
20(2)
Target Blood Pressure
22(1)
Nonmodifiable Risk Factors
22(1)
Family History
22(1)
Age
22(1)
Gender
22(1)
Genetic Markers
23(1)
Hormonal Status And Hormonal Therapy
23(1)
Inflammation
24(3)
C-Reactive Protein
24(1)
Homocysteine and B Vitamins
25(1)
Lipoprotein-associated Phospholipase A2
25(1)
Infections and Cardiovascular Disease
26(1)
Antiplatelet Drugs For Primary And Secondary Prevention
27(3)
Aspirin
27(1)
Primary Prevention Trials
27(1)
Secondary Prevention Trials
27(2)
Clopidogrel
29(1)
References
30(80)
General Articles
30(1)
Lipids and Cholesterol
31(23)
Guidelines
31(1)
Epidemiology
32(2)
Primary Prevention
34(1)
Early Trials
34(1)
Statins in Primary Prevention
35(1)
Combination Therapy in the Statin Era
37(1)
Secondary Prevention
38(1)
Placebo-controlled Trials
38(1)
Intensive- versus Standard-dose Statin Regimens in Stable CAD
41(1)
Early Statin Initiation in ACS
42(2)
Combined Primary and Secondary Prevention Trials
44(1)
Primary and Secondary Prevention Trials in Patients with Comorbidities
45(1)
Meta-analyses and Noncholesterol Effects of Statins
46(2)
HDL-raising Therapies
48(1)
Niacin
48(1)
CETP Inhibitors
50(1)
Meta-analyses and General Studies
52(1)
Novel Classes of Lipid-lowering Agents
52(2)
Antioxidants, Vitamins, Fish Oil, Chelation, and Hormones
54(7)
Observational Studies
54(1)
Clinical Trials
55(5)
Meta-analyses
60(1)
Diet
61(3)
Observational Studies
61(1)
Clinical Trials
62(2)
Alcohol
64(1)
Lifestyle
64(10)
Guidelines and General Articles
64(3)
Obesity and Weight Loss
67(3)
Exercise
70(2)
Smoking
72(1)
Epidemiology
72(1)
Smoking Cessation
74(1)
Metabolic Syndrome and Diabetes
74(6)
Epidemiology
74(2)
Treatment
76(4)
Hypertension
80(17)
Epidemiology and Risk Factors
82(1)
Studies of Treatment
82(1)
Nonpharmacologic Therapies
82(1)
Medical Therapy
84(1)
Diabetes and Hypertension
92(1)
Invasive Therapies
94(1)
Meta-analyses
95(2)
Nonmodifiable Risk Factors
97(1)
Age and Genetics
97(1)
Inflammation
98(8)
C-Reactive Protein
98(2)
Homocysteine and B Vitamins
100(1)
Observational Studies
100(1)
Trials and Meta-analyses
102(1)
Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
103(1)
Infections and Cardiovascular Disease
104(1)
Antibiotic Trials
104(1)
HIV-related Cardiovascular Risk
104(1)
Miscellaneous
105(1)
Antiplatelet Drugs for Primary and Secondary Prevention
106(4)
Primary Prevention
106(1)
Secondary Prevention
107(1)
General Review Articles and Meta-analyses
108(2)
Chapter 2 Coronary Revascularization and Percutaneous Procedures 110(105)
Christopher P. Cannon
Benjamin A. Steinberg
Justin M. Dunn
Coronary Angiography
110(1)
Indications
110(1)
Flow Grade
110(1)
Stenosis Morphology
111(1)
Percutaneous Coronary Intervention
111(24)
Uses and Indications
111(1)
Operator and Hospital Volume
112(1)
Procedural Details
113(4)
Access
113(1)
Contrast Agent
113(1)
Lesion Evaluation
113(2)
Balloon Angioplasty
115(1)
Stenting
116(1)
Medications
117(6)
Aspirin
117(1)
Heparin
117(1)
Low Molecular Weight Heparin
117(1)
Direct Thrombin Inhibitors
118(1)
Thienopyridines/ADP Receptor Antagonists
118(3)
Glycoprotein IIB/IIIA Inhibitors
121(1)
Abciximab (ReoPro)
122(1)
Eptifibatide (Integrilin)
122(1)
Tirofiban (Aggrastat)
123(1)
Applications of PCI
123(3)
Stable Angina
123(1)
Unstable Angina/Non—ST Elevation Myocardial Infarction
124(1)
Acute ST Elevation Myocardial Infarction
124(1)
After Thrombolytic Therapy
124(1)
Stenting versus Percutaneous Transluminal Coronary Angioplasty: Major Trials
125(1)
Direct Stenting versus Balloon Predilatation
125(1)
Repeated Intervention
125(1)
Complications
126(3)
Early Complications
126(1)
Later Complications
127(1)
Stent Thrombosis
127(1)
Restenosis
127(1)
Renal Dysfunction
128(1)
Other Postprocedural Complications
128(1)
Treatment and Prevention of Restenosis
129(4)
Drug Studies
129(1)
Radiation Therapy
129(1)
Drug-eluting Stents
129(2)
Directional Atherectomy
131(2)
Rotational Atherectomy
133(1)
Prevention of Distal Embolization
133(2)
Thrombectomy
133(1)
Distal Protection
134(1)
Coronary Artery Bypass Surgery
135(3)
Coronary Artery Bypass Surgery versus Medical Therapy
135(1)
Coronary Artery Bypass Surgery versus Percutaneous Coronary Intervention
136(2)
Internal Mammary Artery
138(1)
Saphenous Vein Grafts
138(1)
Transcatheter Aortic Valve Replacement
138(2)
Balloon-expandable TAVR
139(1)
Self-expanding TAVR
139(1)
References
140(75)
Guidelines and Classification
140(1)
Operator and Hospital Characteristics
141(2)
Catheterization Technique
143(1)
Contrast Agents
144(2)
Lesion Evaluation (Fractional Flow Reserve, Intravascular Ultrasound)
146(1)
Comparison of Revascularization with Medical Therapy
147(2)
Stent Studies
149(10)
Early Stent Comparisons
149(2)
Provisional Stenting
151(2)
Direct Stenting
153(1)
Drug-eluting Stents
153(6)
Additional Devices/Techniques
159(11)
Cutting Balloon
159(2)
Atherectomy Studies
161(2)
Radiation Therapy
163(4)
Thrombectomy
167(1)
Distal Protection
168(2)
Adjunctive Pharmacologic Therapy
170(15)
Aspirin
170(1)
Heparin
170(1)
Low Molecular Weight Heparin
171(1)
Thienopyridines
172(6)
Glycoprotein IIB/IIIA Inhibitors
178(6)
Thrombin Inhibitors
184(1)
Special Situations
185(5)
Chronic Total Occlusions
185(1)
Bypass Graft Lesions
186(1)
Small Vessels
187(2)
Diabetes
189(1)
Complications
190(4)
Postintervention CK/CK-MB and Troponin Studies
190(1)
Stent Thrombosis
191(1)
Other Complications
192(2)
Coronary Restenosis
194(7)
Repeat Percutaneous Coronary Intervention for Restenosis after Percutaneous Transluminal Coronary Angiography
194(2)
Effect of Stent Design
196(1)
Drug Studies
197(4)
Coronary Artery Bypass Graft Surgery
201(11)
Coronary Artery Bypass Graft Surgery versus Medical Therapy
202(1)
Coronary Artery Bypass Graft Surgery versus Percutaneous Transluminal Coronary Angiography
203(7)
Graft and Patency
210(2)
Transcatheter Aortic Valve Replacement
212(3)
Chapter 3 Unstable Angina/Non—ST Elevation MI 215(51)
Christopher P. Cannon
Benjamin A. Steinberg
Matthew W. Sherwood
Epidemiology
215(1)
Pathophysiology
215(1)
Classification
215(2)
Unstable Angina
215(2)
Non—ST-elevation Myocardial Infarction
217(1)
Clinical And Laboratory Findings
217(3)
History and Symptoms
217(1)
Electrocardiogram
217(1)
Cardiac Enzymes
217(3)
Creatine Kinase and Creatine Kinase-MB
217(1)
Troponins T and I
218(1)
Myoglobin
218(1)
Estimation of Early Risk at Presentation
218(2)
Treatment
220(9)
Aspirin
220(1)
ADP Receptor Antagonists
220(1)
PAR-1 Receptor Antagonists
221(1)
Heparin
221(1)
Low-molecular-weight Heparin
222(1)
Direct Thrombin Inhibitors
223(1)
Factor Xa Inhibitors
224(1)
Glycoprotein IIB/IIIA Inhibitors
224(2)
Intravenous Agents
224(1)
Oral Agents
225(1)
Thrombolytic Therapy
226(1)
Anti-ischemic Medications
226(1)
β-Blockers
226(1)
Nitrates
226(1)
Calcium Channel Blockers
227(1)
3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors (Statins)
227(1)
Invasive Strategy
227(2)
Coronary Artery Bypass Graft Surgery
229(1)
Noninvasive Evaluation
229(1)
Exercise Treadmill Test
229(1)
Exercise Treadmill Testing with Nuclear Imaging
229(1)
Pharmacologic Stress Testing with Imaging
229(1)
Echocardiography
229(1)
Coronary Computerized Tomography Angiography
230(1)
Prognosis And Biomarkers
230(1)
Unstable Angina
230(1)
Non—ST-elevation Myocardial Infarction
230(1)
Prior Aspirin Use (Aspirin Failures)
230(1)
Electrocardiography
230(1)
Troponin Levels
230(1)
C-Reactive Protein
231(1)
B-Type Natriuretic Peptide
231(1)
References
231(35)
Review Articles and Pathophysiology
231(1)
Drugs and Studies
232(22)
Aspirin
232(2)
Thienopyridines
234(2)
PAR-1 Receptor Antagonists
236(1)
Unfractionated Heparin and Warfarin
237(2)
Low-molecular-weight Heparin
239(4)
Anti-ischemic Medications
243(2)
Direct Thrombin Inhibitors
245(1)
Factor Xa Inhibitors
246(1)
Glycoprotein IIB/IIIA Inhibitors
247(6)
Thrombolytics
253(1)
Invasive versus Conservative Management
254(4)
Noninvasive Assessment and Prognosis
258(3)
Clinical or General Analyses
259(2)
Biomarkers
261(5)
Review Articles and Multimarker Studies
261(1)
Troponins
262(1)
High-sensitivity Troponins
263(1)
Inflammatory Markers
263(1)
B-Type Natriuretic Peptide
264(1)
Specific Tests: Angiography, ECG, and Holter
265(1)
Chapter 4 ST Elevation Myocardial Infarction 266(108)
Christopher P. Cannon
Benjamin A. Steinberg
Justin M. Dunn
Epidemiology
266(1)
Pathogenesis
266(2)
Diagnosis
267(1)
Chest Pain
267(1)
Electrocardiography
267(1)
Echocardiography
267(1)
Biomarkers
267(1)
Treatment
268(19)
Aspirin
268(1)
P2Y12 Inhibitors
269(1)
β-Blockers
270(1)
Angiotensin-converting Enzyme Inhibitors
271(1)
Aldosterone Antagonism
272(1)
Thrombolytic Therapy
272(4)
Indications for Thrombolysis
273(1)
Contraindications
274(1)
Common Fibrinolytic Agents
274(1)
Streptokinase
274(1)
Tissue Plasminogen Activator
274(1)
Reteplase
275(1)
Tenecteplase
275(1)
Prognostic Indicators
276(1)
Percutaneous Coronary Intervention
276(5)
Primary Angioplasty
276(1)
Procedural Volume
277(1)
Primary Angioplasty versus Thrombolysis
277(1)
Rescue Angioplasty
278(1)
Routine PCI (after Thrombolysis) versus Delayed or Conservative Management
278(1)
Facilitated Percutaneous Coronary Intervention
279(1)
Cardiogenic Shock
280(1)
Stenting in STEMI
280(1)
Antithrombotic Regimens
281(4)
Heparin
281(1)
Enoxaparin
281(1)
Fondaparinux
282(1)
Direct Thrombin Inhibitors
282(1)
Oral Anticoagulants
283(1)
Intravenous Glycoprotein IIB/IIIA Inhibitors
284(1)
Use in Primary PCI
284(1)
Glycoprotein IIb/IIIa Inhibition Plus Reduced-dose Thrombolysis
285(1)
Other Therapies
285(2)
Nitrates
285(1)
Calcium Channel Blockers
285(1)
Antiarrhythmics
286(1)
Magnesium
286(1)
Glucose—Insulin—Potassium
286(1)
Intra-aortic Balloon Pump
287(1)
Right Ventricular Infarction
287(1)
Diagnosis
287(1)
Complications
288(1)
Treatment
288(1)
Complications Of Stemi
288(2)
Early
288(1)
Intermediate
289(1)
Late
289(1)
Prognosis And Risk Stratification After Myocardial Infarction
290(3)
Uncomplicated STEMI
290(1)
Complicated Course
291(1)
Specific Tests
292(1)
References
293(81)
General Review Articles and Guidelines
293(1)
Epidemiology
293(1)
Pathogenesis
294(1)
Diagnosis
295(3)
Chest Pain and Symptoms
295(1)
Electrocardiography
295(1)
Biomarkers
296(1)
Prehospital and Emergency Department Evaluation
297(1)
Treatment
298(62)
Aspirin
298(1)
P2Y12 Inhibitors
299(2)
β-Blockers
301(3)
Angiotensin-converting Enzyme Inhibitors
304(1)
Reviews and Meta-analyses
304(1)
Studies
305(3)
Thrombolytic Therapy
308(1)
Review Articles and Meta-analyses
308(1)
Thrombolytic Comparative Studies
309(1)
Prehospital Thrombolysis Studies
316(2)
Percutaneous Coronary Intervention
318(1)
Reviews
318(1)
Meta-analyses
318(1)
Primary PCI
319(1)
PCI after Thrombolysis
322(1)
Rescue PCI
328(1)
Operator and Hospital Volumes
329(1)
Stenting in STEM!
329(4)
Antithrombotic Regimens
333(1)
Antithrombins
333(1)
Direct Thrombin Inhibitors
336(1)
Oral Anticoagulants
339(1)
Glycoprotein IIb/IIIa Inhibitors
343(1)
Glycoprotein IIb/IIIa Inhibitors and Reduced-dose Thrombolysis
345(3)
Other Therapies
348(1)
Nitrates
348(1)
Calcium Channel Blockers
348(1)
Antiarrhythmics
350(1)
Magnesium
353(1)
Glucose—Insulin—Potassium
354(1)
Infarct Types
355(1)
Left Ventricular Infarctions
355(1)
Right Ventricular Infarction
357(1)
Treatment of Cardiogenic Shock
357(1)
Percutaneous Assist Devices
358(2)
Assessment and Prognosis
360(9)
Reviews and Meta-analyses
360(1)
Electrocardiography, Arrhythmias, and Conduction Disease
361(2)
Exercise Testing
363(1)
Echocardiography and Other Noninvasive Tests
364(1)
Flow, Vessel Patency, and Angiography
364(3)
Other Prognostic Factors
367(2)
Complications of Myocardial Infarction
369(9)
Arrhythmias, Bundle Branch Block
369(1)
Cardiac Rupture
369(1)
Intracranial Hemorrhage in Thrombolysis
370(1)
Reocclusion, Recurrent Ischemia, and Reinfarction
370(2)
Left Ventricular Thrombi
372(1)
Valvular Damage and Septal Defects
372(2)
Chapter 5 Heart Failure 374(54)
Benjamin A. Steinberg
Christopher P. Cannon
Epidemiology
374(2)
History And Physical Examination
376(1)
Etiology
377(1)
Diagnostic Testing
377(1)
Treatment
378(14)
Treatment of Acute Heart Failure
378(2)
Treatment of Chronic Heart Failure
380(11)
Angiotensin-converting Enzyme Inhibitors
380(2)
Angiotensin II Receptor Antagonists
382(1)
Dual Ras Blockade (ACE/ARB)
383(1)
β-Blockers
384(1)
Diuretics
385(1)
Aldosterone Blockers
385(1)
Digoxin
386(1)
Vasodilators
386(1)
Hydralazine and Isosorbide Dinitrate
386(1)
Calcium Channel Blockers
387(1)
Amiodarone
387(1)
Emerging Medical Therapies
387(1)
Biventricular Pacing
388(1)
Surgical Therapies
388(1)
Left Ventricular Assist Device
388(1)
Coronary Artery Bypass Graft Surgery
389(1)
Cardiac Transplantation
390(1)
Other Surgical Treatments
390(1)
Additional Therapeutic Considerations
391(1)
Hemodynamic Monitoring
391(1)
Exercise Training and Rehabilitation
391(1)
Prevention of Sudden Cardiac Death
391(1)
References
392(36)
Guidelines and Reviews
392(1)
Epidemiology
393(1)
Diagnosis and Prognosis
394(4)
Physical Examination
394(1)
Diagnostic Testing
395(2)
Noninvasive Testing
397(1)
Treatment
398(30)
Angiotensin-converting Enzyme Inhibitors and Angiotensin-II Receptor Blockers
398(1)
Meta-analyses
398(1)
Studies
398(5)
β-Blockers
403(1)
Review Articles and Meta-analyses
403(1)
Carvedilol Studies
403(1)
Other Studies
407(2)
Diuretics and Aldosterone Antagonists
409(3)
Digoxin
412(1)
Vasodilators
413(5)
Amiodarone
418(1)
Inotropic and Other Agents
419(2)
Mechanical Assist Devices and Surgical Options
421(3)
Invasive Therapy
424(1)
Additional Therapeutic Considerations
425(1)
Anticoagulation
425(1)
Exercise
426(2)
Chapter 6 Arrhythmia 428(73)
Benjamin A. Steinberg
Christopher P. Cannon
Atrial Arrhythmias
428(17)
Epidemiology
428(1)
Natural History
428(1)
Etiologies and Risk Factors
429(1)
Stroke Risk Factors
430(1)
Treatment
430(15)
Rate versus Rhythm Control
430(2)
Pharmacologic Agents for Control of the Ventricular Rate
432(1)
Pharmacologic Agents for the Acute Conversion of Atrial Fibrillation
433(1)
Intravenous Agents
433(1)
Oral Agents
434(2)
Pharmacologic Agents for Long-term Maintenance of Sinus Rhythm
436(2)
Catheter and Surgical Ablation
438(1)
Catheter Ablation
438(1)
Surgical Ablation
439(1)
Electrical Cardioversion
439(1)
Type and Amount of Energy
439(1)
Anticoagulation before and after Cardioversion
440(1)
Prevention of Thromboembolism
441(1)
Long-term Anticoagulation
441(1)
Non—Vitamin K Oral Anticoagulants
443(1)
Other Strategies to Prevent Thromboembolism
444(1)
Other Treatment Measures
444(1)
Atrial Pacemakers
444(1)
Atrioventricular Junction Ablation with Permanent Pacemaker Implantation
444(1)
Atrial Fibrillation Prevention after Cardiac Surgery
444(1)
Ventricular Arrhythmias
445(6)
Immediate Therapy: Automated External Defibrillators
445(1)
Immediate Therapy: Intravenous Amiodarone
446(1)
Secondary Prevention Trials: Drugs versus Implantable Cardioverter—Defibrillators
446(3)
Primary Prevention Trials: Antiarrhythmic Drugs
449(1)
Primary Prevention Trials: Drugs versus Implantable Cardioverter—Defibrillators
449(1)
Primary Prevention Trials: Nonischemic Cardiomyopathy Patients
450(1)
Studies of Emerging Tachyarrhythmia Therapies
451(1)
Cardiac Pacing Studies
451(3)
Pacemaker Mode Selection Trials
451(1)
Pacing for Vasovagal Syncope
452(1)
Pacing for Prevention of Atrial Fibrillation
452(1)
Resynchronization Therapy for Congestive Heart Failure
453(1)
References
454(47)
Atrial Fibrillation
454(1)
Guidelines
454(1)
Epidemiology
454(1)
Risk Stratification
455(2)
Rate versus Rhythm Control
457(1)
Drug Trials for Rate and Rhythm Control in Atrial Fibrillation
458(9)
Catheter and Surgical Ablation
467(1)
Catheter Ablation
467(1)
Surgical Ablation
469(1)
Electrical Cardioversion and Pericardioversion Anticoagulation
470(2)
Long-term Anticoagulation
472(5)
Non—Vitamin K Oral Anticoagulants
477(4)
Nonpharmacologic Stroke Prevention in AF
481(1)
Atrial Fibrillation Prevention after Surgery
481(1)
Ventricular Arrhythmias
482(9)
Guidelines
482(1)
Immediate Therapy: Automated External Defibrillators
482(1)
Immediate Therapy: Intravenous Amiodarone
483(1)
Secondary Prevention Trials: Drugs versus Implantable Cardioverter—Defibrillators
484(1)
Primary Prevention Trials: Antiarrhythmic Drugs
485(1)
Primary Prevention Trials: Drugs versus Implantable Cardioverter—Defibrillators
486(3)
Primary Prevention Trials: Nonischemic Cardiomyopathy Patients
489(1)
Studies of Emerging Tachyarrhythmia Therapies
490(1)
Cardiac Pacing Studies
491(10)
Guidelines
491(1)
Mode Selection Trials
491(2)
Pacing for Vasovagal Syncope
493(2)
Pacing for Prevention of Atrial Fibrillation
495(1)
Resynchronization Therapy for Congestive Heart Failure
495(6)
Trial Index 501(12)
Subject Index 513
More information about ebooks More information about ebooks
Permanent link: https://www.kriso.ee/db/97814963751176e.html
Keywords: